Literature DB >> 25603050

MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma.

Lianyong Liu1, Jingnan Wang1, Xiangqi Li1, Junhua Ma1, Chao Shi1, Hongling Zhu1, Qian Xi1, Jichen Zhang1, Xuemei Zhao1, Mingjun Gu2.   

Abstract

microRNAs (miRNAs) are frequently dysregulated in human malignancies. It was recently shown that miR-204-5p is downregulated in papillary thyroid carcinoma (PTC); however, the functional significance of this observation is not known. This study investigated the role of miR-204-5p in PTC. Overexpressing miR-204-5p suppressed PTC cell proliferation and induced cell cycle arrest and apoptosis. The results of a luciferase reporter assay showed that miR-204-5p can directly bind to the 3' untranslated region (UTR) of insulin-like growth factor-binding protein 5 (IGFBP5) mRNA, and IGFBP5 overexpression partially reversed the growth-inhibitory effects of miR-204-5p. These results indicate that miR-204-5p acts as a tumor suppressor in PTC by regulating IGFBP5 expression and that miR-204-5p can potentially serve as an antitumorigenic agent in the treatment of PTC.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IGFBP5; Papillary thyroid carcinoma; Proliferation; miR-204-5p

Mesh:

Substances:

Year:  2015        PMID: 25603050     DOI: 10.1016/j.bbrc.2015.01.037

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  53 in total

1.  miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.

Authors:  Rui Li; Jia Liu; Qun Li; Guang Chen; Xiaofang Yu
Journal:  Tumour Biol       Date:  2015-10-19

2.  MicroRNA-204 suppressed proliferation and motility capacity of human hepatocellular carcinoma via directly targeting zinc finger E-box binding homeobox 2.

Authors:  Bin Hu; Ming Sun; Jiajun Liu; Guolin Hong; Qin Lin
Journal:  Oncol Lett       Date:  2017-03-24       Impact factor: 2.967

3.  [Effect of miR-204-5p on the proliferation, migration, and invasion on tongue squamous cell carcinoma SCC25 cells by targeting bromodomain-containing protein 4].

Authors:  Jing Zheng; Yu-Wen Zhang; Tian-Ke Li; Yang Bao; Su-Xin Zhang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-04-01

4.  MiR-203a-3p, miR-204-3p, miR-222-3p as useful diagnostic and prognostic tool for thyroid neoplasia spectrum.

Authors:  Stefana Stojanović; Zorana Dobrijević; Sonja Šelemetjev; Ilona Đorić; Jelena Janković Miljuš; Vladan Živaljević; Tijana Išić Denčić
Journal:  Endocrine       Date:  2022-09-14       Impact factor: 3.925

Review 5.  Noncoding RNA actions through IGFs and IGF binding proteins in cancer.

Authors:  Aidan Kerr; Robert C Baxter
Journal:  Oncogene       Date:  2022-05-21       Impact factor: 8.756

6.  Effects of nutraceuticals on anaplastic thyroid cancer cells.

Authors:  Lorenzo Allegri; Francesca Rosignolo; Catia Mio; Sebastiano Filetti; Federica Baldan; Giuseppe Damante
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-02       Impact factor: 4.553

7.  IGFBP5 promotes diabetic kidney disease progression by enhancing PFKFB3-mediated endothelial glycolysis.

Authors:  Chengcheng Song; Shuqiang Wang; Zhangning Fu; Kun Chi; Xiaodong Geng; Chao Liu; Guangyan Cai; Xiangmei Chen; Di Wu; Quan Hong
Journal:  Cell Death Dis       Date:  2022-04-13       Impact factor: 8.469

8.  Decreased Expression of MiRNA-204-5p Contributes to Glioma Progression and Promotes Glioma Cell Growth, Migration and Invasion.

Authors:  Zhiqiang Xia; Fang Liu; Jian Zhang; Li Liu
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

9.  Novel circular RNA expression profile of uveal melanoma revealed by microarray.

Authors:  Xuan Yang; Yang Li; Yueming Liu; Xiaolin Xu; Yingzhi Wang; Yanni Yan; Wenjia Zhou; Jingyan Yang; Wenbin Wei
Journal:  Chin J Cancer Res       Date:  2018-12       Impact factor: 5.087

10.  miR-195 is a key regulator of Raf1 in thyroid cancer.

Authors:  Fangzheng Wang; Chuner Jiang; Quanquan Sun; Fenqin Yan; Lei Wang; Zhenfu Fu; Tongxin Liu; Fujun Hu
Journal:  Onco Targets Ther       Date:  2015-10-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.